Edgewise Therapeutics, Inc. - Common Stock (NQ:EWTX)

41.52 +0.12 (+0.29%)

Delayed Quote Updated: 12:46 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Edgewise Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Edgewise Therapeutics Reports Second Quarter 2022 Financial Results

August 04, 2022

From Edgewise Therapeutics, Inc.

Via Business Wire

Edgewise Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on August 9

August 03, 2022

From Edgewise Therapeutics

Via Business Wire

6 Blue-Chip Stocks to Sell Now ↗

July 18, 2022

This article is about 6 blue-chip stocks to sell now. They are severely overvalued or are likely to move down soon with a recession.

Via InvestorPlace

Edgewise Therapeutics Initiates Mid-Stage Muscular Dystrophies Study ↗

July 12, 2022

Edgewise Therapeutics (NASDAQ: EWTX) announced the initiation of the CANYON Phase 2 clinical trial evaluating EDG-5506 in individuals with Becker Muscular Dystrophy (BMD).

Via Benzinga

Edgewise Therapeutics Now Enrolling CANYON Phase 2 Clinical Trial of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD)

July 12, 2022

From Edgewise Therapeutics

Via Business Wire

RBC Capital Says This Dystrophy Stock 'Is Worth A Look' ↗

June 22, 2022

Via Benzinga

Edgewise's Dystrophy Candidate Lowers Muscle Damage Biomarkers ↗

June 21, 2022

Via Benzinga

The Daily Biotech Pulse: Thumbs Down For Acadia's Pimavanserin, Pfizer Buys Stake In Valneva, AstraZeneca - Ionis Eplontersen Aces Rare Disease Trial ↗

June 21, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)

June 20, 2022

From Edgewise Therapeutics

Via Business Wire

New 2-Month Interim Data from the ARCH Open Label Study of EDG-5506 in Individuals with Becker Muscular Dystrophy (BMD) to be Presented at the Upcoming New Directions in Biology and Disease of Skeletal Muscle Conference

June 16, 2022

From Edgewise Therapeutics

Via Business Wire

Recap: Edgewise Therapeutics Q1 Earnings ↗

May 11, 2022

Edgewise Therapeutics (NASDAQ:EWTX) reported its Q1 earnings results on Wednesday, May 11, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Stocks That Hit 52-Week Lows On Friday ↗

March 25, 2022

On Friday, 166 companies set new 52-week lows. Points of Interest From Today's 52-Week Lows: The largest company by market cap to set a new 52-week low was...

Via Benzinga

Edgewise Therapeutics to Present at Upcoming Investor Conferences

May 31, 2022

From Edgewise Therapeutics

Via Business Wire

Analyst Ratings for Edgewise Therapeutics ↗

May 12, 2022

Over the past 3 months, 4 analysts have published their opinion on Edgewise Therapeutics (NASDAQ:EWTX) stock. These analysts are typically employed by large Wall Street banks and tasked with...

Via Benzinga

Edgewise Therapeutics Reports First Quarter 2022 Financial Results

May 11, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Present at Upcoming Investor Conferences

May 03, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise-Funded Natural History Trial of Becker Muscular Dystrophy (BMD) Now Enrolling

April 14, 2022

From Edgewise Therapeutics

Via Business Wire

Stocks That Hit 52-Week Lows On Wednesday ↗

March 23, 2022

On Wednesday, 63 companies set new 52-week lows. Noteworthy Mentions In Today's 52-Week Lows: The largest company by market cap to hit a new 52-week low was...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

March 24, 2022

On Thursday, 112 stocks made new 52-week lows. Noteworthy Highlights From Today's 52-Week Lows: Stanley Black & Decker (NYSE:SWK) was the largest firm by market...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study ↗

March 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗

March 13, 2022

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...

Via Benzinga

Edgewise Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

February 24, 2022

From Edgewise Therapeutics

Via Business Wire

Edgewise Therapeutics to Participate at SVB Leerink 11th Annual Global Healthcare Conference on February 16

February 02, 2022

From Edgewise Therapeutics

Via Business Wire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

January 28, 2022

Gainers Provention Bio (NASDAQ:PRVB) stoc...

Via Benzinga

Stocks Move Higher Midday, Still Pacing for Weekly Losses ↗

January 28, 2022

Stocks are continuing their rollercoaster pattern midday, as Wall Street attempts to lift itself out of the worst selloff since March 2020.

Via Talk Markets

52 Biggest Movers From Friday ↗

January 31, 2022

Gainers Knightscope, Inc. (NASDAQ: KSCP) surged 175.6% to close at $3.40 on Friday. The company, on Thursday, priced its IPO at $10 per share. Imperial Petroleum Inc. (NASDAQ:...

Via Benzinga

33 Stocks Moving In Friday's Mid-Day Session ↗

January 28, 2022

Gainers Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 126% to $2.6219. Imperial Petroleum, last month, posted Q3 revenue of $4.1 million. Yoshitsu Co., Ltd (NASDAQ: TKLF...

Via Benzinga

50 Biggest Movers From Yesterday ↗

January 06, 2022

Gainers Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) shares surged 63.7% to settle at $2.21 on Wednesday after the company announced that in preclinical studies its lead...

Via Benzinga

Mid-Afternoon Market Update: Nasdaq Down 300 Points; Annexon Shares Plunge ↗

January 05, 2022

Toward the end of trading Wednesday, the Dow traded up 0.24% to 36,711.36 while the NASDAQ fell 1.93% to 15,321.38. The S&P also fell, dropping 0.80% to 4,755.18. The U.S. has...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

January 05, 2022

Gainers Lixte Biotech Holdings (NASDAQ:LIXT) stock increased by 70.4% to $2.3 during Wednesday's regular session. Trading volume for this security as of 12:31 EST is...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.